



# AAX Biotech and ToxoTech Join Forces to Advance Next-Generation Biotherapeutics for Neurological Disorders

**AAX Biotech AB, specializing in innovative technologies for improving antibody-based medicines, and ToxoTech AB, a biopharmaceutical company developing therapies for neurological disorders, today announced a strategic collaboration to advance next-generation biotherapeutics. The partnership applies AAX's Seqitope® platform in a new therapeutic area, expanding its use beyond antibody epitope mapping.**

The co-development study combines AAX Biotech's proprietary Seqitope® platform with ToxoTech's expertise in biologic drug design to create novel biotherapeutic candidates with improved potency and precision. By applying Seqitope® to optimize receptor recognition, the collaboration aims to generate novel variants with potential as treatments for neuromuscular and neurological indications.

"This project represents an exciting new application of Seqitope® beyond its established use in antibody epitope mapping," says Daniel X Johansson, CEO/CSO of AAX Biotech. "With our cutting-edge technologies to advance biologic drug discovery, we are pleased to collaborate with ToxoTech and leverage Seqitope® to guide rational design and accelerate the development of precision-engineered biologics."

"At ToxoTech, we bring extensive experience in the drug design of biotherapeutics for neurology, and we see Seqitope® as a valuable complement to our discovery pipeline. Working together with AAX Biotech allows us to accelerate the development of innovative therapies with the potential to transform treatment options across neurological and neuromuscular indications", says Geoffrey Masuyer, CEO of ToxoTech.

This partnership reflects a shared vision between the two companies to accelerate the development of precision biologics and broaden future treatment options. By integrating Seqitope®'s high-resolution insights with ToxoTech's innovative therapeutic approach, the project aims to open new avenues in the creation of advanced therapies.

**For more information, please contact:**

Maria Lisa Knudsen, CBO, AAX Biotech  
+46 72 939 5018

[maria.knudsen@aaxbiotech.com](mailto:maria.knudsen@aaxbiotech.com)

Geoffrey Masuyer, CEO, Toxotech  
[geoffrey.masuyer@toxotech.se](mailto:geoffrey.masuyer@toxotech.se)

**About AAX Biotech AB**

AAX Biotech AB is a biotech company specializing in next-generation antibody therapeutics. The company offers two unique and proprietary technologies, Seqitope® and Opti-mAb®, that enable high throughput and high-resolution epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Both technologies aim to produce better and more effective antibody-based medicines. These innovations position AAX Biotech as a key player in the rapidly growing antibody therapeutics market. AAX Biotech is founded by experts from Karolinska Institutet in Stockholm, Sweden. Visit [aaxbiotech.com](http://aaxbiotech.com) to learn more and follow [AAX Biotech on LinkedIn](#).

**About ToxoTech AB**

ToxoTech AB is a Stockholm-based biopharmaceutical company developing novel biotherapeutics for neurological applications. With a platform focused on enhancing therapeutic precision and efficacy, ToxoTech aims to deliver innovative solutions for patients living with neuromuscular and neurological disorders. Learn more: <http://toxotech.se/>